A fixed dose combination of nivolumab and relatlimab is in development for the treatment of advanced and metastatic melanoma patients that have not received previous treatment. Melanoma is a cancer of the skin, when is advanced or metastatic, the cancer has spread to other organs and tissues such as lymph nodes and the brain. Metastatic melanoma can present a range of different symptoms including lumps under the skin, swollen lymph nodes, bone pain and headaches. At this stage the cancer can’t be cured.
Nivolumab works by improving the activity of white blood cells increasing the ability of the immune system to kill cancer cells. Relatlimab has the potential to increase the immune system response and kill cancer cells. If licenced for this indication, a fixed dose combination of intravenous nivolumab and relatlimab may provide a new therapeutic option for untreated patients that shows similar adverse effects than treatment with nivolumab alone.
Brigatinib is a medicinal product that is being developed for the treatment of patients with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) whose disease have progressed following treatment with alectinib or ceritinib. NSCLC is the most common type of lung cancer although a small proportion of NSCLC patients have a rearrangement in the ALK gene. Locally advanced or metastatic cancer means cancer has spread outside the lungs where it started, to other parts of the body and cannot be cured. Current treatment with drugs such as alectinib or ceritinib are effective in slowing the disease and helping patients to live longer, although some patients eventually develop treatment resistance and will require other therapies.